PITTSBURGH — Mylan has agreed to pay $30 million in a settlement tied to its failure to tell investors about a Justice Department investigation into whether the company overcharged Medicaid for the EpiPen.
RELATED: Lawsuit alleges Mylan, other pharma companies conspired to inflate drug prices
The Securities and Exchange Commission said Friday that Mylan NV classified the EpiPen as a “generic” drug under the Medicaid drug rebate program. This led to the pharmaceutical company paying much lower rebates to the government than if the EpiPen had been classified as a “branded” drug.
Mylan had disclosed in July that it had reached an agreement-in-principle with the SEC on the matter. The company said in a statement Friday that it neither admits nor denies the SEC’s allegations.
TRENDING NOW:
- Elizabeth Bridge closed indefinitely due to ‘structural concerns,’ officials say
- Police searching for 7-week-old believed to be in danger
- Sisters beaten during fight at Pittsburgh gas station speak out day after surveillance released
- VIDEO: Young people might be turning to black market for vape products
- DOWNLOAD the Channel 11 News app for breaking news alerts
Associated Press
/cloudfront-us-east-1.images.arcpublishing.com/cmg/XCUXZC2XYZHCRGNNGKFEX6U3LQ.png)
